News Understanding Sysmex

Select your local Sysmex website

JAPAN

AMERICAS

EMEA

ASIA PACIFIC

GLOBAL HEADQUARTERS (JAPAN)

REGIONAL HEADQUARTERS

OTHER SYSMEX GROUP COMPANIES

  1. Home
  2. Research & Development
  3. Technology Awards
  4. Sysmex Receives “JCA-Nagayama Award” by the Japanese Cancer Association (JCA) for "Initiation of Cancer Genomic Medicine through the Clinical Implementation of the NCC Oncopanel"

Research & Development

Technology Awards

Sysmex Receives “JCA-Nagayama Award” by the Japanese Cancer Association (JCA) for "Initiation of Cancer Genomic Medicine through the Clinical Implementation of the NCC Oncopanel"

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) has received the JCA-Nagayama Award from the Japanese Cancer Association for the research theme "Initiation of Cancer Genome Medicine through Medical Implementation of the NCC Oncopanel" conducted by a research and development group (10 members) including doctors from the National Cancer Center.

The JCA-Nagayama Award honors individuals or groups who have conducted research and development related to new anticancer drugs and treatments, creating significant contributions to the advancement of cancer medicine in Japan. Established in 2010, the award is named after Osamu Nagayama, the founder of the supporting foundation, the Chugai Pharmaceutical Science Foundation. 
 
Award Details 
Title of the award: Initiation of Cancer Genomic Medicine through the Clinical Implementation of the NCC Oncopanel
Winners:  Noboru Yamamoto1), Takashi Kohno1), Kenji Tamura2), Hitoshi Ichikawa1),
Mamoru Kato1), Kuniko Sunami1), Satoshi Nakajima3), Atsushi Ochiai4)1),
Reiko Watanabe5), Takaaki Washio6)
1) National Cancer Center Japan
2) Shimane University
3) SEKISUI MEDICAL CO., LTD.
4) Tokyo University of Science
5) Sysmex Corporation
6) RIKEN Genesis Co., Ltd.
Date of the award:  September 23, 2023
Description of
the invention: 		 Sysmex has established the Sysmex Cancer Innovation Laboratory
(SCI-Lab) within the National Cancer Center Hospital, adhering to
international standards, to facilitate the early introduction of cancer
clinical sequencing tests into clinical practice. At this facility,
Sysmex has participated in the TOP-GEAR project, a clinical study
aimed at utilizing the genomic profiles of cancer tissues to
determine treatment strategies, in collaboration with RIKEN Genesis.
Based on the results of this research, Sysmex obtained manufacturing and
marketing approval in Japan in 2018 for the OncoGuide™ NCC Oncopanel
System, the country's first cancer-related gene panel testing, and received
insurance coverage in 2019. These efforts have contributed to the
advancement of comprehensive cancer genome medicine in Japan.
Recognizing these initiatives, the research and development group
(10 members), including doctors from the National Cancer Center (NCC),
has been awarded the JCA-Nagayama Award by the Japanese Cancer
Association.
Currently, the OncoGuide™ NCC Oncopanel System, along with other
cancer gene panel testing, is making significant contributions to cancer
genome medicine in Japan.

  • Information contained in the technology awards is current as of the date of the announcement,
    but may be subject to change without prior notice.

Back to "Technology Awards"